VERO

Venus Concept Inc. is a global medical technology company. The Company develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services and reaches over 60 countries and nine direct markets. The Company’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Versa Pro, Venus Legacy, Venus Velocity, Venus Viva, Venus Glow, Venus Bliss, Venus Bliss MAX, Venus Epileve, Venus Viva MD and AI.ME. Its treatments for hair loss are divided into non-surgical options and surgical procedures. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. Its systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family medicine and general practitioners and aesthetic medical spas.

Wall Street analysts forecast VERO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VERO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Venus Concept Inc revenue for the last quarter amounts to 13.78M USD, decreased -8.20 % YoY.

Venus Concept Inc. EPS for the last quarter amounts to -12.14 USD, decreased -13.78 % YoY.

Venus Concept Inc (VERO) has 292 emplpoyees as of December 16 2025.

Today VERO has the market capitalization of 3.10M USD.